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The global coronavirus disease 2019 pandemic continues to
escalate at a rapid pace inundating medical facilities and
creating substantial challenges globally. The risk of severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
infection in patients with cancer seems to be higher, espe-
cially as they are more likely to present with an immuno-
compromised condition, either from cancer itself or from
the treatments they receive. A major consideration in the
delivery of cancer care during the pandemic is to balance
the risk of patient exposure and infection with the need to
provide effective cancer treatment. Many aspects of the
SARS-CoV-2 infection currently remain poorly characterized
and even less is known about the course of infection in the
context of a patient with cancer. As SARS-CoV-2 is highly
contagious, the risk of infection directly affects the cancer
patient being treated, other cancer patients in close prox-
imity, and health care providers. Infection at any level for
patients or providers can cause considerable disruption to
even the most effective treatment plans. Lung cancer pa-
tients, especially those with reduced lung function and
cardiopulmonary comorbidities are more likely to have
increased risk and mortality from coronavirus disease 2019
as one of its common manifestations is as an acute respi-
ratory illness. The purpose of this manuscript is to present a
practical multidisciplinary and international overview to
assist in treatment for lung cancer patients during this
pandemic, with the caveat that evidence is lacking in many
areas. It is expected that firmer recommendations can be
developed as more evidence becomes available.
 2020 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
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In December of 2019, an atypical pneumonia of un-
known origin was reported in patients in Wuhan, thePeople’s Republic of China. The source was thought to be a
wet market called the Huanan Seafood Wholesale Market.
Subsequently, it was determined that the agent respon-
sible was an enveloped RNA beta coronavirus, designated
as severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2, or 2019-nCoV)1 (Fig. 1). The condition
associated with the SARS-CoV-2 virus was named Coro-
navirus Disease 2019 (COVID-19), and it was designated a
pandemic by WHO on March 11, 2020. Genomic charac-
terization of the virus determined that the agent was
distinct from other coronaviruses like severe acute respi-
ratory syndrome coronavirus 1 (SARS-CoV-1) and Middle
East respiratory syndrome.2 SARS-CoV-2 is highly infec-
tious. As of May 3, 2020, there were 3.6 million docu-
mented cases globally with, 248,000 deaths, resulting in a
case fatality rate of 6.9%. However, these numbers are
likely to be inaccurate given that asymptomatic infections
occur and the rate of testing in different countries ranges
from four people out of 1 million population being tested
in Yemen to 146,000 tested out of 1 million population in
Iceland.3 Patients with cancer are at a heightened risk for
developing serious complications from COVID-19.4,5 As a
group, they tend to be of advanced age and have an
increased risk of relative immunosuppression from the
underlying malignancy and anticancer treatments.
Furthermore, patients with lung cancer may have addi-
tional comorbidities, including a history of smoking and
preexisting lung disease. There are challenges in the
management of a patient with lung cancer given the sim-
ilarities in radiologic findings, respiratory symptoms, and
the presence of underlying immunosuppression. In addi-
tion, immune checkpoint inhibitors are now widely used
in the management of advanced lung cancer. Immune-
related pneumonitis from these agents could mimic
COVID-19 radiologically. In this article, we aim to provide
guidance in the management of lung cancer patients dur-
ing this period through a multidisciplinary perspective on
the basis of clinical experience and the available data in
the literature.
Figure 1. This is a scanning electron microscope image,
which shows severe acute respiratory syndrome coronavirus 2
(round blue objects) emerging from the surface of cells
cultured in the laboratory. Severe acute respiratory syn-
drome coronavirus 2, also known as 2019 novel coronavirus,
is the virus that causes coronavirus disease 2019. The virus
exhibited here was isolated from a patient in the United
States. Adapted from National Institute of Allergy and In-
fectious Diseases - Rocky Mountain Laboratories (NIAID-RML).
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According to WHO and Centers for Disease Control
and Prevention (CDC), the preferred current diagnostic
method is the detection of SARS-CoV-2 nucleic acid in
patient specimens.6,7 SARS-CoV-2 preferentially pro-
liferates in type II alveolar cells (AT2) and the peak of
viral shedding appears 3 to 5 days after the onset of
disease. Therefore, an initial negative nucleic acid test
does not exclude a positive on subsequent days, as the
negative predictive value is relatively low. Appropriate
samples include the upper airways (pharyngeal swabs,
nasal swabs, nasopharyngeal secretions), the lower air-
ways (sputum, bronchoalveolar lavage fluid specimens),
and also blood, feces, urine, and conjunctival secretions.
Sputum and other lower respiratory tract specimens
have a high positive rate of nucleic acids.8 When test
material is scarce, the diagnosis and case definition can
be made on the basis of clinical symptoms and radiologic
characteristics.9 WHO has advised every country to
establish and publish their case definitions appropriate
for their region.
Serologic tests are currently being developed. How-
ever, because of a lack of sensitivity of a number of tests,
and more importantly, the delay from the time of infec-
tion to antibody development, these tests may instead
serve as a useful tool for population-based analysis for
epidemiologic purposes, whereas reverse transcription–
polymerase chain reaction (RT-PCR) remains the best
methodology to detect acute infections.Disease Characteristics
The main modes of SARS-CoV-2 transmission are
through respiratory droplets and contact,10-12 whereas
airborne transmission may be possible for situations in
which aerosols are generated, such as endotracheal
intubation and during bronchoscopy.13 The mean incu-
bation period in patients is approximately 4 to 5.2 days
and the mean serial interval, or time between the onset
of symptoms in one individual and onset in a serial in-
dividual, is 7.5 days.11,14,15 Viral load is more similar to
influenza and it does not differ between symptomatic
and asymptomatic patients.16 Like SARS-CoV-1, the
SARS-CoV-2 virus seems to use the angiotensin-con-
verting enzyme 2 (ACE2) receptor to enter host cells.17
ACE2 receptors are highly expressed in cells in blood
vessels, heart, kidney, and AT2 cells in the lungs. The
latter is important for the synthesis, storage, and secre-
tion of surfactant, a substance that prevents atelectasis
of lung tissue by lowering the surface tension of alveoli.
The destruction of AT2 cells may play a key role in the
development of severe pulmonary symptoms in patients
with COVID-19. It has been shown that the ACE2 re-
ceptor is markedly more expressed in chronic obstruc-
tive pulmonary disease patients, and in current smokers
versus former smokers (compared with never-smokers)
and shows an inverse relationship with forced expira-
tory volume in 1 second.18
Recent reports from the People’s Republic of China
and Italy suggest that approximately 60% to 90% of
patients present with fever, 55% to 70% with cough, and
33% with dyspnea.19 Other symptoms, which includes
nausea, vomiting, and diarrhea, were observed in less
than 5% of patients. In the United States, the CDC added
other symptoms to this list—myalgia, fatigue, headache,
sore throat, and new-onset loss of taste or smell. Labo-
ratory abnormalities such as lymphopenia (83.2%),
thrombocytopenia (36.2%) and leukopenia (33.7%)
were observed in hospitalized patients.14 Radiologic
findings will be discussed in a subsequent section.
Approximately 15% to 20% of patients will develop
severe symptoms and may require hospitalization and
intensive care. Severe complications may include bilat-
eral pneumonia (75%) acute respiratory distress syn-
drome (17%) and multiorgan failure (11%).20-22
Emerging data indicate that vascular inflammation can
result in diffuse microangiopathy with thrombosis,
which contributes to multiorgan failure. In addition,
pulmonary embolism, myocardial ischemia, and cere-
brovascular accidents have been reported (Table 1).23
Those with the most severe disease on hospitaliza-
tion tend to be older and have preexisting underlying
diseases.14,24 Among the 355 patients who died from
COVID-19, 70% were men, 30% had ischemic heart
Table 1. Symptoms, Signs, and Complications of
Coronavirus Disease 2019
Type Symptom or Sign
Common symptoms or
signs (2–14 d after
exposure): >30%
 Fever
 Cough with or without
expectoration
 Shortness of breath or difficulty
catching a breath
Other symptoms:
5%–15%
 Headache
 Body aches
 Diarrhea
 Vomiting
 Tiredness
 Aches
 Runny nose
 Sore throat
Rare symptoms or
signs <5%
 Loss of smell
 Loss of taste
 Sudden confusion
 Disorientation
 Seizures
 Bluish lips, face, or toes
 Gangrenous distal digits
Complications  Pneumonia in both lungs/ARDS 17%
 Organ failure in several organs 11%
 Microangiopathy with thrombosis 31%
ARDS, acute respiratory distress syndrome
4 Dingemans et al Journal of Thoracic Oncology Vol. - No. -disease, 36% had diabetes, 25% had atrial fibrillation,
and 20% had cancer.25 Only 0.3% had no preexisting
diseases. Patients with a higher Sequential Organ Failure
Assessment score and D-dimer greater than 1 mg/mL
were found to be at higher risk for death from COVID-
19.24 Any potential relationship between the smoking
status of the patients and the onset or severity of the
disease remains unknown.
Diagnostic Strategies for Patients With Lung
Cancer
The primary aim of diagnosis in a patient with sus-
pected lung cancer is to obtain tissue specimens for
histologic diagnosis, using the least invasive method. But
the risk of spreading SARS-CoV-2 infection needs to be
considered. In addition, there is a risk of slow-down of
diagnostic procedures as patients are afraid of going to
the hospital during the current pandemic. Bronchoscopy,
an aerosol-generating procedure, should be avoided
whenever possible.
The American Association for Bronchology and
Interventional Pulmonology has issued a statement on
the safe and effective use of bronchoscopy in patients
with suspected or confirmed COVID-19.26 The following
applies to suspected and confirmed patients with lung
cancer:
 Elective Bronchoscopy for lung mass, bronchial mass,
mediastinal, or hilar lymphadenopathy, lung infiltrates,and mild-to-moderate airway stenosis should be
postponed until after full recovery from COVID-19;
 Bronchoscopy for urgent or emergent reasons should
be considered with all precautionary measures only if
it is a lifesaving intervention, e.g., massive hemoptysis,
benign or malignant severe airway stenosis or suspi-
cion of an alternative or secondary infectious cause or
malignant condition with a resultant substantial
endobronchial obstruction or rapidly progressing
malignancy.
The Society of Interventional Radiology has catego-
rized all procedures, such as transthoracic needle bi-
opsies, as elective, urgent, and emergent.27 Procedures
that can be delayed or rescheduled in cases of worsening
local infection rates should be determined on an indi-
vidual basis.Pathologic Features
Pathologically, in the early and presymptomatic
phase, the lungs exhibit exudation of proteinaceous fluid,
mixed with patchy inflammatory cellular infiltrates and
focal reactive hyperplasia of type II pneumocytes.
Although patchy alveolar epithelial injury can be seen,
hyaline membrane formation, a pivotal feature of diffuse
alveolar damage, is not evident.28
In severe and fatal cases, limited gross findings from
autopsy studies have shown large areas of lung consol-
idation and hemorrhage, with mucus plugs evident in
small airways.29 Damage to alveolar epithelial cells with
desquamation and mononuclear inflammatory cell infil-
tration in airspaces has been observed.30,31 Thin to quite
prominent hyaline membranes, hyperplasia of type II
pneumocytes, congestion of septal capillary vessels, and
microthrombi are also frequently seen.30,32 In addition
to these changes of ongoing diffuse alveolar damage,
alveolar hemorrhage, and consolidation by fibroblastic
proliferation with the extracellular matrix and fibrin-
forming clusters in airspaces can be prominent.30,32
Others have observed mucous plugs in the alveoli and
bronchioles and the activation of alveolar macro-
phages.33 In some patients, consolidation consisted of
abundant intra-alveolar neutrophils, consistent with
superimposed bacterial bronchopneumonia.30
Several studies have suggested the presence of
fibrosis in the lungs of COVID-19 patients.32,33 How-
ever, it seems this mainly corresponds to microscopic
findings of fibroblast proliferation with early extra-
cellular matrix production in small airways and air-
spaces, with thickened alveolar walls and interstitial
areas with increased stromal cells and CD4-positive
lymphocytes.30-32 Whether or not true pulmonary
fibrosis occurs in COVID-19 patients will depend on
longitudinal follow-up of the long-term survivors,
--- 2020 Guidance for Lung Cancer in COVID-19 5especially when symptoms appear and biopsies, when
indicated, are examined.
In summary, on the basis of limited data that is
currently available, the basic underlying pathology of
COVID-19 pneumonia seems to be that of diffuse alveolar
damage with varying degrees of organization. In addi-
tion, embolic events are frequent with vascular damage.Imaging Features of SARS-CoV-2 Infection
(COVID-19) and Implications for Patients With
Lung Cancer
Typical chest radiographic features of COVID-19 pa-
tients include consolidation with limited cases of pleural
effusion.34 Chest radiographs are less sensitive in the
detection of COVID-19 with a sensitivity of around 30%
to 70%.35 However, with the current limitations in
diagnostic availability and kit performance, the total
positive rate of RT-PCR from nasopharyngeal swabs has
been reported to be 59% at the initial presentation.36 It
is in this setting that European radiologists have used
diagnostic algorithms to evaluate the use of first-line
triage diagnostic radiographs.34
The Radiological Society of North America has
recently published an Expert Consensus Statement on
Reporting Chest Computed Tomography (CT) Findings
Related to COVID-19.37 This attempts to categorize CT
findings of COVID-19 pneumonia into typical, indeter-
minate, atypical appearances, and negative for
pneumonia.37 The typical CT appearances specific for
COVID-19 pneumonia is listed as peripheral, bilateral
ground-glass opacities (GGOs) with or without consoli-
dation or visible intralobular lines (crazy paving),
multifocal GGO or rounded cellular structure with or
without consolidation or visible intralobular lines and
reverse halo sign or other findings of organizing pneu-
monia (seen later in the disease).
The main CT findings of COVID-19 based on the
duration of symptom onset so far described are the
following38-40:
(1) Early stage: 0 to 4 days after onset of flulike symp-
toms; normal CT scans in up to 50% of patients or
scans with small subpleural GGO (Fig. 2A), mainly in
the lower lobes. Typical CT findings are infrequently
observed.
(2) Progressive stage: 5 to 8 days after onset of symp-
toms; peripheral focal or multifocal GGO affecting
both lungs in approximately 50% to 75% of patients,
which then rapidly develop into crazy paving pattern
and areas of consolidation, typically affecting both
lungs (Fig. 2B).
(3) Peak stage: 9 to 13 days after onset of symptoms; as
the disease progresses, crazy paving andconsolidation with air bronchograms become the
dominant findings (Fig. 3A and B).
These stages are then followed by a slow clearing
starting approximately at (but not before) one month
after onset of symptoms. The reported sensitivities of CT
images for COVID-19 were 60% to 98% but had a low
specificity (25% to 53%).41 CT features such as bilateral
involvement, peripheral distribution, and lower zone
dominance can also be assessed on chest radiograph.34
A noncontrast CT scan is recommended as intrave-
nous contrast may mask subtle GGO.38 Axial recon-
struction should be performed without a gap on 0.625 to
5 mm axial slice thickness depending on institutional
logistics, data storage, and processing capabilities.
Atypical CT findings are only seen in a small minority
of patients and should raise concern for superimposed
bacterial pneumonia or other differential diagnoses.39
Such findings include the following: mediastinal lymph-
adenopathy, pleural effusions, multiple tiny pulmonary
nodules, tree-in-bud opacities, and cavitation. Pneumo-
thorax and the halo sign are also rarely seen.20,42
The American College of Radiology does not recom-
mend the use of chest radiograph or CT for the screening
of COVID-19 in patients without symptoms as imaging
findings are not specific and may overlap with those of
other infections and acute lung injury manifesting as
organizing pneumonia pattern from drug toxicity, con-
nective tissue disease, or idiopathic causes.41,43 Howev-
er, in symptomatic patients with a high suspicion of
COVID-19 but negative PCR, CT scan may make the
diagnosis much more likely, especially in individuals
without pulmonary comorbidities.What Does All of This Mean for Patients With
Lung Cancer?
GGO and consolidation in COVID-19 could mimic
radiotherapy- or chemotherapy and immunotherapy-
associated pneumonitis and viral infections, although
they tend to be more peripheral. The chemotherapy and
immunotherapy-associated pneumonitis seems to be
more confluent and perihilar.44 In addition, CT findings
suggestive of COVID-19 may be incidentally encountered
in patients with lung cancer at the time of diagnosis
(Fig. 2A) or posttreatment. In such situations, the risk of
infection should be evaluated by a multidisciplinary
team including clinicians and radiologists along with
history and the consideration of RT-PCR testing.
It is also important to highlight that CT pulmonary
angiography might represent a valuable tool for detec-
tion of pulmonary thromboembolism and subsequent
management in patients with COVID-19 pneumonia. In
fact, elevated D-dimer and thromboembolism are
Figure 2. (A) Early stage COVID-19 CT findings: axial CT im-
age of the lungs of a 67-year-old Italian man presenting with
hemoptysis. This CT image exhibits a left upper lobe mass
(arrowhead) histologically proven to be adenocarcinoma.
There are also peripheral, subpleural GGOs (arrowed) and
the patient was confirmed on second throat RT-PCR swab test
to also have COVID-19. (B) Progressive stage COVID-19 CT
findings: reconstructed axial lung image from a CT-PET scan
done for the same patient 2 days later, which exhibited
progression of the GGOs into areas of crazy paving (arrows)
and consolidation (arrowheads). COVID-19, coronavirus dis-
ease 2019; CT, computed tomography; GGOs, ground-glass
opacities; PET, positron emission tomography; RT-PCR,
reverse transcription–polymerase chain reaction.
Figure 3. Peak stage COVID-19 CT findings: axial CT images of
the mediastinum (A) and lungs (B) of a 54-year-old Chinese
man on day 13 of onset of symptoms exhibiting large bilateral
pleural effusions with dense dependent consolidation at the
lower lobes (arrows). Trivial pericardial effusion is also seen
(arrowhead). Partially imaged ECMO catheter overlying the
right anterior chest wall. COVID-19, coronavirus disease
2019; CT, computed tomography; ECMO, extracorporal
membrane oxygenation.
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cially those with severe lung damage.45
In summary, although imaging is not recommended
as the first line for the screening of COVID-19 in most
guidelines, it is currently used in clinical practice in most
Western countries at diagnosis and can be used as an
adjunct for follow-up of disease progression. The main
finding of GGO and consolidation in COVID-19 may
mimic treatment-induced pneumonitis (Figs. 4A and B)
or viral pneumonia in lung cancer patients.Management of COVID-19
Currently, there is no specific validated treatment for
COVID-19, and management comprises of supportive
and symptomatic care and instituting recommendedinfection prevention and control measures. There are
anecdotal reports and preclinical data supporting the
investigation of potentially efficacious drugs.46 A number
of these including chloroquine and its analogs with or
without azithromycin, antivirals such as remdesivir
(developed against Ebola but found to be ineffective),
lopinavir and ritonavir (anti–human immunodeficiency
viruses), and monoclonal antibodies against interleukin-
6 (tocilizumab47) are currently being studied in clinical
trials globally. Multiple studies are also evaluating the
use of convalescent plasma in patients with severe
COVID-19 (Table 2).
Results from a few studies have been reported. A
study from the People’s Republic of China that
Figure 4. (A) Axial CT lung image of a 73-year-old Chinese
woman with EGFR-positive NSCLC 2 months after starting a
third-generation EGFR-TKI. The upper lobes do not reveal any
abnormality. (B) Axial CT lung image of the same patient 4
months after starting a third-generation EGFR-TKI. The upper
lobes now reveal patchy ground-glass changes (arrows) with
interstitial thickening (arrowheads) in a perihilar distribution
consistent with EGFR-TKI–induced pneumonitis. CT,
computed tomography; TKI, tyrosine kinase inhibitor.
--- 2020 Guidance for Lung Cancer in COVID-19 7randomized 237 symptomatic patients in a 2:1 ratio of
remdesivir or placebo found that remdesivir use was not
associated with a difference in time to clinical improve-
ment (hazard ratio 1.23 [95% confidence interval 0.87–
1.75]). Although it was not statistically significant, pa-
tients receiving remdesivir had a numerically faster time
to clinical improvement than those receiving placebo
among patients with symptom duration of 10 days or
less (hazard ratio 1.52 [95% confidence interval 0.95–
2.43]).48 Furthermore, interim results after the Data and
Safety Monitoring Board mandated the unblinding of a
randomized, placebo-controlled trial involving 1063
hospitalized patients with advanced COVID-19 and lunginvolvement revealed promising results. Patients who
received remdesivir had a 31% faster time to recovery
than those who received placebo (p < 0.001). Specif-
ically, the median time to recovery was 11 days for pa-
tients treated with remdesivir compared with 15 days
for those who received a placebo. Results also suggested
a not statistically significant survival benefit, with a
mortality rate of 8.0% for the group receiving remdesivir
versus 11.6% for the placebo group (p ¼ 0.059).49 This
study conducted by the United States National Institutes
of Health has not been published in the peer-reviewed
literature yet, thus, the results are considered pre-
liminary. However, U.S. Food and Drug Administration
granted the emergency approval of remdesivir for the
treatment of patients with severe COVID-19 on May
1, 2020.Overall Treatment of Patients With Lung Cancer
Guiding Principles. The major goal of lung cancer
management during the COVID-19 pandemic is to mini-
mize the risk of exposing the patient and staff to infec-
tion and at the same time manage all life-threatening
aspects of the disease.
This can be achieved by limiting face-to-face visits
with providers and visits to the clinic or hospital,
whenever possible. Patients who need to physically
come to the hospital need to be screened for symptoms
and tested for SARS-CoV-2 infection if there are any of
the typical symptoms discussed above (also in Table 1).
Whenever possible, patients undergoing any invasive
procedure or systemic chemotherapy plus immuno-
therapy should be tested for COVID-19 infection.
Overall clinical trial accrual, in general, has slowed
down during the pandemic. New patient accrual has
been put on hold at various institutions temporarily. We
recommend that if adequate resources are available,
clinical trial enrollment should continue with reasonable
modifications. To protect trial participants, policy and
procedures are being revised to manage study conduct
in compliance with control of COVID-19 with appro-
priate protocol amendments approved by the institu-
tional review boards and sponsors.
Specific recommendations and considerations for
different stages of lung cancer are discussed below and
outlined in Tables 3 to 5.
Early Stage Lung Cancer. For patients with stage I/II
and resectable stage III NSCLC, treatment is either sur-
gical resection or ablative radiotherapy strategies. The
surgical principles of lung cancer remain the same dur-
ing the COVID-19 outbreak. However, the logistics of
clinical practice for early stage lung cancer may be
modified. If the COVID-19 outbreak is impending, an
Table 2. Salient Select Therapeutic Clinical Trials in the Treatment of Patients With Coronavirus Disease 2019
Class Agent
Mechanism of
Actions Developer Original Use Ongoing Trials
Treatment Of COVID-19
Antiviral Remdesivir inhibit RNA-dependent
RNA polymerase
Gilead
sciences
Ebola and Marburg
virus infections
NCT04252664
NCT04292730
NCT04292899
NCT04280705
NCT04321616
Lopinavir-ritonavir HIV reverse
transcriptase
inhibitors
AbbVie HIV-1 infection NCT04255017
NCT04307693
NCT04321616
NCT04330690
NCT04321174
NCT04328285
EudraCT 2020-001113-21
Favipiravir
(fapilavir)
inhibit RNA-dependent
RNA polymerase
Avigan influenza NCT04346628
NCT04349241
NCT04319900
NCT04351295
NCT04310228
Others Hydroxychloroquine DMARD Multiple Malaria, RA, SLE, Q
fever,
NCT04332991
NCT04336332
NCT04303507
NCT04341870
NCT04332094
NCT04341727
NCT04354428
NCT04325893
NCT04343092
NCT04307693
EudraCT 2020-000890-25
ACE inhibitors ACE-2 inhibitor Multiple Hypertension,
cardiac failure
NCT04330300
NCT04338009
NCT04355429
NCT04353596
NCT04351581
Chloroquine sulfate glycosylation of viral
ACE-2/inhibition of
quinone reductase 2
Multiple Malaria NCT04321616
NCT04303507
NCT04351191
NCT04341727
Azithromycin inhibit mRNA
translation
Pfizer Respiratory tract
infections
NCT04341870
NCT04341727
NCT04336332
NCT04329832
NCT04354428
Convalescent
plasma
passive immunotherapy Multiple NA NCT04355767
NCT04345523
NCT04343755
Treatment of COVID-19–induced Cytokine Storm
Monoclonal Ab Tocilizumab IL-6 receptor
antagonist
Roche RA, GCA, CRS, JIA NCT04306705
NCT04310228
NCT04317092
NCT04331795
NCT04332094
NCT04346355
NCT04335071
NCT04320615
NCT04332913
NCT04335305
NCT04339712
NCT04322773
NCT04345445
(continued)
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Table 2. Continued
Class Agent
Mechanism of
Actions Developer Original Use Ongoing Trials
Sarilumab IL-6 receptor
antagonist
Regeneron,
Sanofi
RA NCT04315298
NCT04322773
NCT04327388
NCT04341870
Lenzilumab Antihuman GM-CSF
monoclonal Ab
Humanigen CRS NCT04351152
Leronlimab Anti-CCR5 receptor Ab CytoDyn HIV-1 infection NCT04343651
NCT04347239
Eculizumab anti-C5 antibody Alexion PNH, atypical HUS NCT04288713
NCT04355494
NCT04346797
ACE, angiotensin-converting enzyme; Ab, antibody; C5, complement C5; CCR5, chemokine receptor 5; COVID 19, coronavirus disease 2019; CRS, cytokine
release syndrome; DMARD, disease-modifying antirheumatic drugs; GCA, giant cell arteritis; HUS, hemolytic uremic syndrome; HIV, human immunodeficiency
virus; IL-6, interleukin-6; JIA, juvenile idiopathic arthritis; NA, not applicable; PNH, paroxysmal nocturnal hemoglobinuria; RA, rheumatoid arthritis; SLE,
systemic lupus erythematosus.
--- 2020 Guidance for Lung Cancer in COVID-19 9important issue is to decide whether to delay resection
or not. Guidance from CDC and most professional soci-
eties indicates that elective surgeries should be
rescheduled if possible.50 The American Society of Clin-
ical Oncology recommended that clinicians and patients
need to make individual determinations on the basis of
potential harms caused by delaying needed cancer-
related resection.51 It has been suggested that in pa-
tients with a recent diagnosis of early stage lung cancer
or those with questionable pulmonary nodules, it is
advisable to reschedule the resection as undergoing
surgical procedure during the incubation period of SARS-
CoV-2 infection may result in a dismal outcome.52
However, the European Association of Medical
Oncology recommends keeping all surgeries as a priority
in the management of early NSCLC. Surgical delays
should generally not be more than 6 to 8 weeks.53
The American College of Surgeons has recently pub-
lished COVID-19 elective case triage guidelines for sur-
gical care focusing on the hospital resources available
depending on the phase of the COVID-19 pandemic.54 In
phase I, a semiurgent setting, they recommended that
surgical intervention be restricted to patients whose
survivorship are likely to be compromised if the resec-
tion is not performed within the next 3 months. For lung
cancer, such cases include solid or predominantly solid
(>50%) lung cancer, presumed lung cancer greater than
2 cm, or node-positive lung cancers. It is also recom-
mended that patients who finished induction therapy
proceed to surgery. Predominantly ground-glass nod-
ules, solid nodules less than 2 cm, or indolent histologic
structure should be deferred. In phase II, an urgent
setting, resection is restricted to patients likely to have
survival compromised if a surgical intervention is not
performed within the next few days, such as tumor-
associated infection or surgical complications.Alternative treatment options, including transferring
patients to a hospital that is in phase I, neoadjuvant
therapy, or stereotactic ablative body radiotherapy are
recommended.
If a SARS-CoV-2 test is positive, surgical resection
should be delayed for 2 to 3 weeks, if possible. If the
patient’s condition is urgent, it is recommended that the
resection proceeds within a specialized negative-
pressure operating room with full personal protection
equipment and postoperative care in a negative-pressure
isolation room. All patients should be retested for SARS-
CoV-2 when delayed resection is rescheduled.
As a specific example, in the setting of a widespread
outbreak throughout the whole region, as experienced in
Lombardy, Italy,25 an approach based on the stage of the
disease and other oncologic clinical evaluations was
implemented. Lung cancer patients were categorized
into two groups: (1) red code, or patients with stage IC,
II or III diseases with a real risk of progression and
patients who already received induction chemo- or
chemoradiation treatment, for which resection should be
guaranteed in 4 weeks; and (2) yellow code, or those
patients with stage I tumor (<2 cm) or indolent malig-
nancies that can be postponed for 1 or 2 months. The
Lombardy region identified and selected several hospital
hubs that should theoretically be “COVID-free” for
oncology cases. Surgical red code cases from other hos-
pitals were diverted to these hub hospitals.
In patients with resectable locally advanced disease
with a single positive mediastinal station (resectable
nonbulky IIIA) or T3N1 tumors, for which surgical
treatment is scheduled after induction therapy,55 the
timing of resection could be planned such that adjuvant
chemotherapy starts at a later date. This approach is
based on two main reasons: (1) to avoid exposing the
patient to the risk of infection during the frequent trips
10 Dingemans et al Journal of Thoracic Oncology Vol. - No. -to and from the hospital for chemotherapy cycles at the
apex of the COVID-19 emergency period; and (2) to
reduce chemotherapy-induced immunosuppression,
which can expose the patient to an increased risk of
COVID-19 and, in case of infection, to serious pulmonary
complications with a delay of potential curative surgical
resection. Neoadjuvant therapy is recommended for
appropriate patients to mitigate any deleterious effects
from postponing surgical intervention for situations in
which surgical services are overwhelmed. In general,
measures that allow home management of cancer pa-
tients are encouraged, including telemedicine and phone
calls replacing physical visits.56
Stereotactic body radiotherapy (SBRT) or stereotactic
ablative radiotherapy is a well-established noninvasive
method of treating early stage (<5 cm) node-negative
NSCLC. Treatment with SBRT results in highly effective
cure and local control rates with minimal risk. The de-
livery of SBRT can involve treatment with 50 Gy to 70 Gy
in as many as 5 to 10 fractions for central tumors but can
be delivered in a single fraction of 24 Gy to 34 Gy for
peripheral tumors of less than 2 cm.57 For patients
whom SBRT is appropriate, careful consideration should
be given to whether treatment should be delivered
immediately or delayed for small slow-growing tumors.
Whenever possible, SBRT fractionation schemes during
the COVID-19 pandemic should be shortened as much as
possible with maximal use of single fraction treatment.
Brachytherapy is another modality for radiotherapy
primarily of early stage, recurrent, or small endobron-
chial obstructive lesions involving the insertion of a
radioactive source to treat small areas with less depo-
sition of radiation dose to surrounding tissues. However,
brachytherapy requires multidisciplinary coordination
in a protected operating room or brachytherapy suite,
patient sedation, bronchoscopy, and planning that in-
creases the risk of exposure to patients and providers.
During the COVID-19 pandemic, it is suggested to
consider avoiding all brachytherapy procedures if there
are any external beam radiotherapy or alternative
options.
Adjuvant therapy is not recommended for stage I
NSCLC patients. For cases in which local conditions
render systemic chemotherapy hazardous resulting in
the inability to start adjuvant cytotoxic chemotherapy,
adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy
could be considered for resected EGFR mutation–
positive NSCLC.58,59 If patients are clinically stable af-
ter adjuvant therapy, follow-up imaging can be delayed
for 3 to 4 months.
Locally Advanced Lung Cancer. The treatment of
locally advanced lung cancer could involve resection,
radiotherapy, and systemic therapy; but most patientswith stage III NSCLC will be treated with combined
concurrent chemoradiotherapy typically consisting of
platinum-based chemotherapy with radiotherapy deliv-
ered as 60 Gy in 30 fractions60 followed by consolidation
durvalumab.61 As the aim of treatment is curative, the
decision for treatment will need to take into consider-
ation factors including the risk of developing COVID-19,
the risk of developing treatment-related toxicities, and
the availability of resources to administer treatment
safely. At this time, the relationship between SARS-CoV-2
infection and severity with chemotherapy, radiotherapy,
or immunotherapy has not been clearly defined, but it
has been reported that anticancer therapy within 14
days of COVID-19 diagnosis was associated with an
increased risk of developing severe complications.20
However, this was not confirmed in the most recent
large-series reports.62-64 Careful consideration should be
given by the institution performing adjuvant therapy,
particularly in frail patients. The start of treatment after
resection should be delayed for as long as possible
consistent with the adjuvant chemotherapy data (up to
12 weeks after resection).
Systemic therapies associated with a reduced risk of
myelosuppression, shorter treatment time, and lower
frequency of treatment visits are recommended. A three-
weekly schedule such as cisplatin plus pemetrexed65
may be reasonable, although one limitation is its longer
infusion time. In contrast, therapies with frequent visits
such as daily66 or weekly schedules should be avoided.
Paclitaxel should also be avoided if possible, given the
need for relatively high doses of steroids as a premed-
ication and the longer infusion time. Because of shorter
infusion time and steroid-sparing properties, nano-
particle albumin-bound paclitaxel may be a preferred
alternative to paclitaxel, if it is available. The use of
granulocyte-colony-stimulating factor (G-CSF) should be
strongly encouraged as prophylaxis for early secondary
prevention of neutropenia, as appropriate.
Though alternative chemoradiotherapy treatment
schemes exist,57 themes for treatment remain largely
consistent: patients must come to the clinic once a day, 5
days per week, for several weeks. This requires daily
contact with other patients, treating staff, and trans-
portation to the clinic, which all represent contact modes
for infection over a prolonged treatment period
An alternative approach is the use of hypofractiona-
tion to decrease the number of radiotherapy fractions. If
clinical resources are strained or if exposure risk is high,
radiotherapy could be delayed but at the risk of
increased mortality,67 so risks and benefits need to be
discussed among the treatment team and the patient.
The contemporary use of alternative fractionation
schemes combined with chemotherapy and immuno-
therapy in the curative setting has not been tested.68
Table 3. Prioritizing Treatment Options for NSCLC
Clinical Scenario
Treatment
Recommendation
Initial
Delay, wk Workup Comments
Stage I, II, and resectable IIIA
Stage I and II, untreated Surgery SBRT for
selected stage I
2–8 Repeat CT scan if
baseline CT >8
wk
Stage I and II, resected Observation (adjuvant
therapy for a subset
of stage II disease)
>8 Expand interval for
CTscans up to 4– 6
mo if
asymptomatic
with 4 y, then
annually after y 5
Consider CT scan but perform
remote follow-up
Stage IIIa resectable single
station
Surgery followed by
chemo þ/- radiation
<2 CT scan every 4 mo
Stage III
Stage III untreated Concurrent
chemotherapy and
radiotherapy but may
start with
chemotherapy for
two cycles
<2 Same Consider cisplatin/ pemetrexed
Consider G-CSF if administering
chemotherapy alone
Stage III completed
chemoradiotherapy
Immune therapy
<2 Usual workup for
immune
checkpoint
therapy
May delay up to 7 wk per the
study, but the sooner the
better
Stage II completed treatment Observation >8 Ct scan every 4 mo Consider CT scan but perform
remote follow-up
Stage IV
Stage IV with actionable targets
Untreated Targeted therapy <2 Start on time, perform safety
assessments as laboratory or
ECG, but do phone clinic
instead of in-person visit.
Consider performing response
assessment after 2 mo
On treatment with disease
control targeted therapy
<2 May expand the
disease
assessment for 3
mo if clinically
stable or longer if
on treatment for
a long period of
time
Do virtual clinics for toxicity
notation, management, and
any sign of disease progression
Stage IV wild-type
Untreated Chemotherapy alone <2 Standard Consider less immune
suppressive agents and use of
growth factors or dose
reduction as appropriate
Chemotherapy and
immune therapy
combination
<2 Standard Need to be very selective
Immune therapy single
agent
<2 Standard Preferred if PD-L1 score >50%
consider the approved longer
interval of dosing
On treatment first line Chemotherapy
Chemotherapy and
immunotherapy
<2 May do imaging
every 3 cycles, if
stable
Consider growth factor, aim for a
lesser number of cycles (4, if
disease stable), and switch to
maintenance
(continued)
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Table 3. Continued
Clinical Scenario
Treatment
Recommendation
Initial
Delay, wk Workup Comments
Immune therapy <2 May do imaging
every 3 mo, if
stable
Consider switching to
maintenance as early as
indicated, use a longer
interval of administration. Skip
cycles if appropriate
<2 May do imaging
every 3 cycles, if
stable.
Use approved longer dosing
intervals and stop at 2 y.
On treatment beyond first-
line
Chemotherapy <2 or 2–8 Extend CT scan to 3
or 4 cycles, if
clinically stable
Consider chemotherapy holidays
for 2–3 cycles interval.
Immunotherapy <2 or 2–8 Extend disease
assessment
interval
Use approved longer dosing
intervals
Completed treatment
No evidence of disease Observation >8 Extend interval of
workup
refer to survival clinics
Presence of disease Observation 2–8 Extend the interval
of workup
per phone clinic
CTcomputed tomography; ECG, electrocardiogram; G-CSF, granulocyte-colony stimulating factor; PD-L1, programmed death-ligand 1; SBRT, stereotactic body
radiation therapy.
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fractions with reasonable toxicity profiles.69-70 Sequen-
tial chemotherapy followed by radiotherapy could be
considered but would expose patients to a prolonged
course of cancer treatment during an ongoing pandemic.
As discussed previously, SARS-CoV-2 infection may
induce radiologic abnormalities similar to radiation-
induced pneumonitis or immunotherapy induced pneu-
monitis. In a patient treated with chemoradiation or an
immune checkpoint inhibitor, presentation with dyspnea
and radiologic evidence of pneumonitis can often pro-
vide a diagnostic challenge. In this situation, after
appropriate investigations, corticosteroid treatment may
be considered for patients who have been tested nega-
tive for COVID-19.
However, the development of new infiltrates during
radiotherapy was exhibited in a case report to precede
COVID-19 symptoms and confirmed infection by 3
days.71 Radiation oncologists can review daily radio-
therapy imaging to ascertain if any new infiltrates
develop and this may prove to be useful for early
detection.
COVID-19 and Immunotherapy. Programmed cell
death protein 1 (PD-1) plays a role in both central and
peripheral immune tolerance. Its ligation by pro-
grammed death-ligand 1 (PD-L1) or programmed death-
ligand 2 leads to inhibition of an ongoing or starting
immune response. PD-1 determines the threshold, the
strength, and duration of an immune response and is
sometimes called the immune “rheostat.” Blocking PD-1by monoclonal antibodies has resulted in anticancer ef-
ficacy. Anti–PD-1 or PD-L1 monoclonal antibodies are
currently approved for many cancer types as a new
standard of care, including first-line and second-line
treatment of NSCLC and first-line treatment of SCLC.72
During an acute viral infection, CD8 T-cells up-
regulate cell-surface PD-1. Blockade of PD-1 at this
stage results in accelerated viral clearance.73-74
Depending on the type of virus, this may be accompa-
nied by more severe inflammation of the infected tissue.
After viral clearance, the expanded virus-specific T-cell
population contracts and T-cell memory is formed. One
type of T-cell memory cells, the so-called tissue-resident
memory T-cells, permanently populate the infected tis-
sue, such as lung tissue, during virus infections of the
lower airways.75 At this stage, expression of PD-1 and its
ligands PD-L1/2 may prevent further tissue damage,
whereas blockade of the PD-1/PD-L1 axis could result in
immunopathology. Also, PD-L1 expression especially
may be differentially regulated during an acute viral
infection. PD-L1 is much more widely expressed
compared with PD-1. Apart from cells belonging to the
hematopoietic lineages, endothelial and parenchymal
cells can also up-regulate PD-L1.76 With an acute viral
infection, in addition to PD-1 expression by CD8 and CD4
T-cells, PD-L1 is also up-regulated by cytokines, espe-
cially interferon type 1 and interferon-g, and by path-
ogen recognition receptors, such as TLR and others,
depending on the type of virus. Expression of PD-L1 by
virus-infected cells may inhibit T-cells from efficiently
eliminating these cells. In other models of acute viral
Table 4. Prioritizing Treatment Options for SCLC
Clinical Scenario
Treatment
Recommendation
Initial
Delay, wk Workup Comments
Limited Stage
Untreated Concurrent chemotherapy
and radiotherapy
<2 standard if radiation therapy is not
available start with
chemotherapy and add XRT as
early as possible
On treatment Concurrent chemotherapy
and radiotherapy
followed by
chemotherapy
<2 standard continue with CCRT, keep cycles
of chemotherapy to 4, use
growth factors away from XRT
Completed treatment PCI 2–8 standard
Observation >8 may delay imaging
for a mo
Flow up by teleclinic
Extensive Stage
Untreated Chemotherapy <2 standard should start on time. Consider
growth factors or dose
reduction, consider oral
etoposide for d 2 and 3
Chemotherapy and
immunotherapy
<2 standard Be selective
On treatment chemotherapy <2 may extend
assessment for 3
cycles if stable
Chemotherapy and
immunotherapy
<2
Completed treatment Observation 2–8 May extend up to 2
mo
if asymptomatic by teleclinic
CCRT, concurrent chemoradiation therapy; PCI, prophylactic cranial irradiation; XRT, radiation therapy.
--- 2020 Guidance for Lung Cancer in COVID-19 13infection, the PD-L1 expression occurring later during
acute infection could limit tissue damage by controlling
PD-1 expressing virus-specific T-cells.76 Hence, ideally,
an immune response proceeds in such a way that viral
clearance is optimal with as little tissue damage as
possible (as reviewed by Schonrich et al.).77 What would
be the effect of blockade of the PD-1/PD-L1 axis during
acute viral infection, such as COVID-19? Could this lead
to a better or worse outcome, to even more tissue
damage? Whether or not this occurs is probably virus-
dependent, and so far, very little is known about
COVID-19. On the basis of current scarce data, it is hard
to predict how checkpoint blockade will influence SARS-
CoV-2 infection. There is an urgent need to collect data
from patients with COVID-19 who are on checkpoint
inhibitor treatment. Recently, a worldwide initiative, the
Thoracic Cancers International COVID-19 Collaboration
(TERAVOLT Registry) has been instituted to collect these
data.62,78 The first analysis, which was done on 200
patients with thoracic cancers, revealed that the overall
mortality rate in thoracic malignancies is 34.6%. How-
ever, many patients were not admitted to intensive care
units. With the present analysis, it seems that immuno-
therapy has no detrimental effect on the outcome of
COVID-19 compared with other treatments. In addition,the multivariable analysis failed to reveal that comor-
bidities were associated with an increased risk of death.
For this reason, it is impossible to identify a category of
patients with thoracic cancer who were at higher risk to
have a severe course of COVID-19. Therefore, prevention
remains the only safeguard for these patients.
Advanced Stage NSCLC. The use of molecular-targeted
therapy, immunotherapy, and chemoimmunotherapy in
advanced NSCLC has resulted in long-term survival in a
proportion of patients. Thus, the decision to initiate or
interrupt treatment poses a challenge for both the pa-
tient and their physicians. As lung cancer–related
symptoms are similar to COVID-19, a careful history
and examination are essential before treatment in order
not to miss COVID-19 infection. All patients and health
care providers should follow the general measures
described in previous sections to minimize exposure and
to reduce side effects. Response evaluation can be de-
ferred from every two cycles to three or four cycles to
reduce the frequency of hospital visits, provided that
patients are clinically stable. Radiologic findings of SARS-
CoV-2 infection are difficult to differentiate from drug-
induced pneumonitis or immune-related pneumonitis,
in which a GGO pattern is dominant. Thus, every patient
Table 5. Miscellaneous Issues Related to Lung Cancer
Lung cancer
screening
All activities should be halted
for the screening of
asymptomatic patients.
Suspected
cancer cases
To be reviewed by virtual multidisciplinary
team and decide case by case.
Smoking
cessation
Impact of coronavirus disease 2019 on lung
should energize tobacco control efforts.
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must be evaluated corresponding diagnostic tests.
Treatment-Naive Patients. Many patients at initial diag-
nosis may require immediate therapy and should be
treated according to institutional guidelines. However,
whenever possible, particularly in high-risk patients
(such as those who are frail, elderly, or with comorbid-
ities), treatment should be delayed if the tumor burden
is low. All decisions should be discussed with the patient
and family. Regimens with low myelosuppressive po-
tential are preferred, and the use of G-CSF should be
used as needed, notwithstanding the standard
guidelines.
For nonsquamous carcinoma with high PD-L1
expression, single-agent pembrolizumab is preferred to
a chemotherapy and PD1 or PD-L1 combination to
reduce the incidence of hematologic or other adverse
effects. Given the concerns about the interaction of
checkpoint inhibitors with COVID-19 and the lack of data
as guidance, in specific cases, it is reasonable if the use of
pembrolizumab is deferred and systemic chemotherapy
alone is administered. For pemetrexed treatment, doses
of dexamethasone can be reduced to minimize
immunosuppression.
Similar to nonsquamous carcinoma, for squamous
carcinoma with high expression of PD-L1, pem-
brolizumab is preferred to a chemotherapy and PD1 or
PD-L1 combination to reduce the incidence of hemato-
logic or other side effects. If a chemotherapy combina-
tion is used, an effort should be made to use the least
myelosuppressive regimen.
Patients on Treatment With Single-Agent Immunother-
apy. For patients on single-agent immunotherapy, a
number of approaches have been proposed to minimize
the risk of infection. One recommendation is to continue
treatment for patients in the early induction phase or
short-term maintenance phase of therapy. In these pa-
tients, every attempt should be made to limit the number
of visits, such as lengthening the duration of cycles. The
pharmacology of most of the immune checkpoint in-
hibitors used in lung cancer lends itself to much less
frequent dosing than currently used.79 The plasma half-lives of atezolizumab, nivolumab, pembrolizumab, and
durvalumab are 27, 26.7, 26, and 12 days respectively.
Currently, nivolumab can be given at a dose of 480 mg
every 4 weeks. Atezolizumab can be given at a 1680 mg
flat-dose, and durvalumab can be given at a dose of 1500
mg every 4 weeks as maintenance for SCLC. These reg-
imens can be adopted for NSCLC. Pembrolizumab at a
dose of 400 mg every 6 weeks for all approved in-
dications just received regulatory approval by the U.S.
Food and Drug Administration and should be the
schedule of choice in the current COVID-19 pandemic.
In patients who have been on therapy for over a year,
consideration could be given to deferring treatments for
even longer periods.
Oncogene-Driven NSCLC. For patients with oncogene-
driven NSCLC who are treated with a TKI, treatment
can continue as prescribed. Follow-up evaluation
through telemedicine is encouraged when possible.
Response evaluation visits can be delayed, and CT scans
are only advised in patients who are suspected of
symptomatic progression. Whenever possible, medica-
tions can be mailed to patients to reduce the need for
frequent visits. For situations in which this is not
possible, the patient’s healthy family member can pick
up the medication from the hospital or clinic.
Although it is quite rare, TKI-induced pneumonitis
might be difficult to distinguish from COVID-19 pneu-
monia. Extensive evaluation and monitoring are
required. Steroids should be avoided as much as
possible. Preliminary results of the TERAVOLT registry
suggest that these patients have a risk of long hospital-
ization compared with those who had other treatments.
SCLC. SCLC is a highly aggressive disease and is char-
acterized by a rapid response to chemotherapy. Post-
poning first-line treatment will therefore rarely be
possible. For patients with limited disease SCLC, the
standard treatment is concurrent chemoradiotherapy, in
which radiotherapy is given twice daily for three weeks
or once daily for 6 weeks with comparable disease
control and toxicity outcomes.80 A shortened treatment
time would facilitate optimal care with a decreased total
time of SARS-CoV-2 exposure risk. The Concurrent ONce
-daily VERses Twice-daily chemotherapy in patients with
limited-stage small-cell lung cancer (CONVERT) trial
revealed that with modern radiotherapy techniques, se-
vere radiotherapy-induced toxicity is limited; however,
more than 70% of patients experience grade 3 to 4
neutropenia.80 Dose reductions should be considered
especially in patients expected to be high risk for both
neutropenia and COVID-19 (i.e., frail, elderly, have hyper-
tension, or undergoing sequential chemoradiotherapy).
--- 2020 Guidance for Lung Cancer in COVID-19 15Given the relatively modest benefit of prophylactic cranial
irradiation and consolidative radiotherapy, it has been
suggested that both can be removed from care patterns.81
It is also suggested that oral etoposide could be considered
an option for SCLC patients during COVID-19 to reduce the
frequency of hospital or clinic visits.
For decades the standard treatment of patients with
metastatic SCLC was etoposide-platinum. Recently,
improved progression-free survival and overall survival
have been shown when atezolizumab was added to
chemotherapy.82 However, the improvement in outcome
is modest and no predictive biomarker is available to the
few patients who will benefit. It is, therefore, reasonable
to omit atezolizumab in patients at high risk of COVID-19
mortality, as described previously. When used, a less
frequent schedule with every 4 weeks of atezolizumab
should be considered. The use of G-CSF or dose re-
ductions of the chemotherapy regimen in patients at a
high risk of neutropenia should be considered. Second-
and further-line treatment should be postponed after a
full discussion with patients and families was done on
the basis of the risk/benefit ratio.Conclusion
The rapid onset of the COVID-19 pandemic requires
careful consideration of urgent decisions to treat lung
cancer by oncologists. Treatment decisions balancing the
risk of exposure with effective care require close multi-
disciplinary discussions and thorough deliberation be-
tween caregivers and patients. The duration and severity
of the COVID-19 pandemic are unclear, and treatment
delay alone will be insufficient to provide optimal
treatment to cancer patients. In combination with
determining a treatment path for lung cancer, physicians
should educate patients to help them prevent further
spread of COVID-19 according to WHO and CDC guide-
lines. Patients who commit to treatment should further
commit to self-isolation and safe practices for them-
selves, other patients, and providers.
COVID-19 will eventually be controlled. However,
outbreaks are likely to recur. To be prepared, a number
of international COVID study groups have been orga-
nized and active participation is encouraged.Acknowledgments
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